Business Context and Reporting Period
Envveno Medical Corp (NVNO) filed this Form 8-K on December 18, 2024, to report the completion of its 2024 Annual Meeting of Stockholders. The company is incorporated in Delaware and its common stock trades on The NASDAQ Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of four proposals voted upon by stockholders. As of the record date, 17,535,948 shares were entitled to vote, with 11,366,486 shares present or represented by proxy.
- Proposal 1 (Election of Class I Directors): Dr. Francis Duhay and Dr. Sanjay Shrivastava were elected to three-year terms expiring in 2027.
- Dr. Duhay: 3,607,466 votes For; 2,459,268 votes Withheld.
- Dr. Shrivastava: 4,618,871 votes For; 1,447,863 votes Withheld.
- Proposal 2 (Executive Compensation): Stockholders approved the non-binding advisory resolution on named executive officer compensation.
- 3,255,160 votes For; 2,665,653 votes Against; 145,921 Abstaining.
- Proposal 3 (Say-on-Pay Frequency): Stockholders selected "1 Year" as the preferred frequency for future advisory votes on executive compensation.
- 3,976,538 votes For 1 Year; 1,630,287 votes For 3 Years; 330,459 votes For 2 Years.
- Proposal 4 (Auditor Ratification): The appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.
- 11,071,482 votes For; 233,605 votes Against; 61,399 Abstaining.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly limited to the tabulation of votes from the Annual Meeting.
Investor Verification Checklist
- Verify the official appointment of Marcum LLP as the auditor for the fiscal year ending December 31, 2024.
- Confirm the tenure of the newly elected Class I directors (Dr. Duhay and Dr. Shrivastava) through the 2027 annual meeting.
- Note the shareholder preference for annual "Say-on-Pay" votes, which will dictate the frequency of future executive compensation advisory votes.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.